Mesenchymal stromal cell therapy for Crohn's disease

Area of Science:

• Immunology
• Regenerative Medicine
• Gastroenterology

Background:

• Current Crohn's disease (CD) treatments do not fully address its pathogenesis.
• Mesenchymal stromal cells (MSCs) possess immunomodulatory properties and differentiation potential.
• MSCs can be sourced from adipose tissue, bone marrow, or umbilical cord.

Purpose of the Study:

• To review the therapeutic potential of MSC therapy for Crohn's disease.
• To discuss the immunomodulatory mechanisms of MSCs in CD.
• To highlight preclinical and clinical findings for MSC treatment in fistulizing CD.

Main Methods:

• Review of preclinical studies in experimental colitis models.
• Analysis of clinical studies involving MSC therapy for fistulizing CD.
• Examination of MSC characteristics and pharmacological interactions in CD patients.

Main Results:

• MSC therapy is a feasible and safe option for refractory fistulizing CD.
• Repeated administrations of autologous and allogeneic MSCs show potential efficacy.
• Ongoing phase 3 trials are evaluating the definitive efficacy of MSC therapy.

Conclusions:

• MSC therapy, primarily through immunomodulation, offers a novel therapeutic avenue for Crohn's disease.
• Understanding MSC characteristics in CD patients is crucial for optimizing treatment.
• Further research and clinical trials are recommended to address limitations and confirm efficacy.